LivaNova (LIVN) EBT Margin (2014 - 2026)

LivaNova (LIVN) posted EBT Margin of 7.59% for Q1 2026, down 0.91% sequentially from 7.66% in Q4 2025, and up 10721.0% YoY from N/an in Q1 2025.

LivaNova (LIVN) EBT Margin (2014 - 2026) Analysis & Trends

LivaNova has reported EBT Margin for 13 years, with the latest figure at 7.59% in Q1 2026.

Quarterly EBT Margin rose 10721.0% year-over-year to 7.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.54% (up 2368.0% YoY) and the FY2025 annual result came in at 15.91%, down 2295.0% from the prior year.
EBT Margin eased to 7.59% in Q1 2026 per LIVN's latest filing, from 7.66% in the prior quarter.
Over five years, EBT Margin peaked at 17.55% in Q4 2024 and troughed at 99.62% in Q1 2025.
A 5-year average of 5.54% and a median of 3.71% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2025 and 2026: EBT Margin tumbled 8802 bps in 2025, then surged 10721 bps in 2026.
Over 5 years, EBT Margin stood at 2.33% in 2022, then plunged by 1407 bps to 30.41% in 2023, then jumped by 158 bps to 17.55% in 2024, then slumped by 56 bps to 7.66% in 2025, then fell by 1 bps to 7.59% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 7.59%, 7.66%, and 9.48% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	200.11 Bn	194.51 Bn	7.27 Bn	12.10%
2	Stryker	129.85 Bn	126.37 Bn	4.50 Bn	23.74%
3	Medtronic	119.93 Bn	110.71 Bn	6.41 Bn	18.70%
4	Boston Scientific	74.18 Bn	73.64 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	52.54 Bn	48.29 Bn	1.35 Bn	29.86%
6	Dexcom	34.76 Bn	32.81 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	34.25 Bn	32.14 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.45 Bn	23.13 Bn	4.55 Bn	8.91%
9	Steris	23.29 Bn	22.80 Bn	684.20 Mn	18.32%
10	LivaNova	4.33 Bn	3.81 Bn	273.67 Mn	4.73%

Download Data